Aldevron, a leading provider of antibody discovery and production services, today announced the successful discovery of human antibodies utilizing the combination of three powerful platforms, Aldevron’s GENOVAC^® genetic immunization and cell-based screening, Ligand’s OmniRat^® therapeutic antibody platform and Berkeley Lights’ Beacon^® platform.

Aldevron LLC, a company angling for a role in the production of Covid-19 vaccines, hired Rachel Lei as its first general counsel and corporate secretary.

Lei became Aldevron’s first general counsel in June. She joins new chief executive officer Kevin Ballinger, hired the following month, among other recent additions to the North Dakota-based company’s leadership team.

Rachel Lei has joined Aldevron as its new General Counsel and Corporate Secretary. Lei will advise the Board of Directors and CEO on issues of overarching importance to Aldevron and will assist in setting and implementing Aldevron’s overall strategic direction , building and overseeing Aldevron’s legal department to ensure that its legal function operates as a true business partner.

A plasmid DNA manufacturer is planning to scale up its production capacity to meet the growing needs of gene therapy. Aldevron, a company based in North Dakota, expects to open a new 189,000 sq. ft facility in spring 2021 to add to their existing 70,000 sq. ft of manufacturing space.